Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp428 | Osteoporosis: treatment | ECTS2013

Persistence with different anti-osteoporosis medications: a population-based cohort study.

Pages-Castella Aina , Carbonell-Abella Cristina , Nogues Xavier , Javaid M Kassim , Arden Nigel K , Cooper Cirus , Diez-Perez Adolfo , Prieto-Alhambra Daniel

Objective: Several reports suggest very low persistence with oral bisphosphonates, but there is a scarcity of data on persistence with other anti-osteoporosis medications. We therefore compared rates of early discontinuation (in the first year of therapy) between all available outpatient anti-osteoporosis drugs in Catalonia, Spain.Study design: population-based retrospective cohort study.Participants and source of data: The data in...

ba0003pp192 | Genetics | ECTS2014

Genetic determinants of bone mineral density loss in aromatase inhibitors treatment in the B-ABLE Cohort

Rodriguez-Sanz Maria , Garcia-Giralt Natalia , Torres-del Pliego Elisa , Prieto-Alhambra Daniel , Servitja Sonia , Balcells Susana , Mellibovsky Leonardo , Grinberg Daniel , Tusquets Ignasi , Diez-Perez Adolfo , Nogues Xavier

Bone density (BMD) loss is a consequence of aromatase inhibitors (AI) treatment of breast cancer. B-ABLE cohort includes 391 postmenopausal women with early breast cancer starting AI therapy. Participants experienced a 1.98% (95% CI 1.54–2.42% P<0.0001) bone loss at lumbar spine (LS) and 1.24% (95% CI 0.81–1.67% P<0.0001) bone loss at femoral neck (FN) after 1 year on AI therapy and a 3.51% (95% CI 3.00–4.03% P<0.0001) bone...

ba0003pp239 | Osteoporosis: evaluation and imaging | ECTS2014

Impact of metal artefacts in QCT of the hip caused by a contralateral Gamma type nail: an ex vivo study

Engelke Klaus , Bouler Nicolas , Fuerst Oleg Museyko , Parratte Sebastien , Fuerst Thomas , Pion Francois-Xavier , Champsaur Pierre , Genant Harry , Corroller Thomas Le

Introduction: Gamma type nails are routinely used for the fixation of intertrochanteric fractures of the proximal femur. QCT at the hip is an advanced method that is increasingly being used to estimate BMD and determine the future fracture risk. Yet, implants cause metal artefacts (MA) in CT images, even at the contralateral side due to the high absorption of metal, which may impair BMD accuracy.Methods: Three human cadavers were scanned first without an...

ba0005ahp.oc1.3 | Abstract Presentations | ECTS2016

Treat-to-target in osteoporosis. Mith or reality? Results of a spanish Delphi study

Munoz-Torres Manuel , Casado Enrique , Jodar Esteban , Nogues Xavier , Nolla Joan Miquel , Quesada-Gomez Jose Manuel , Canals Laura , Balcells Monica , Lizan Luis

Objective: To define, by expert consensus, the criteria for the application of a Treat-to-Target (T2T) strategy in osteoporosis, in Spain, and to assess the adequacy of current treatments for it.Material and methods: Six Spanish experts in osteoporosis formed the Scientific Committee that led the project and designed the questionnaire used in two Delphi rounds. The 24 items included in the questionnaire assessed the experts’ wish (W) and prognosis (...

ba0005p239 | Genetics and Epigenetics | ECTS2016

Search for BMD-related variants of DKK1 and SOST by resequencing in the BARCOS cohort

Martinez-Gil Nuria , Roca-Ayats Neus , Urreizti Roser , Franco-Valls Hector , Garcia-Giralt Natalia , Mellibovsky Leonardo , Nogues Xavier , Diez-Perez Adolfo , Grinberg Daniel , Balcells Susana

In a meta-analysis by Estrada et al. (2012), 56 loci were found associated with BMD, 14 of which were also associated with osteoporotic fracture. Several of these genes belong to the Wnt signaling pathway, including two inhibitors: DKK1 and SOST.To better understand the role of these genes in BMD determination and fracture susceptibility, we aimed to explore their allelic architecture by resequencing all coding exons and flanking region...

ba0005p408 | Osteoporosis: treatment | ECTS2016

Treat-to-target in osteoporosis. Mith or reality? Results of a Spanish Delphi study

Munoz-Torres Manuel , Casado Enrique , Jodar Esteban , Nogues Xavier , Nolla Joan Miquel , Quesada-Gomez Jose Manuel , Canals Laura , Balcells Monica , Lizan Luis

Objective: To define, by expert consensus, the criteria for the application of a Treat-to-Target (T2T) strategy in osteoporosis, in Spain, and to assess the adequacy of current treatments for it.Material and methods: Six Spanish experts in osteoporosis formed the Scientific Committee that led the project and designed the questionnaire used in two Delphi rounds. The 24 items included in the questionnaire assessed the experts’ wish (W) and prognosis (...

ba0001pp61 | Bone development/growth and fracture repair | ECTS2013

Vascularisation and progenitor cells of primary and secondary ossification centres in the human growth plate

Walzer Sonja M , Cetin Erdal , Grubl-Barabas Ruth , Sulzbacher Irene , Ruger Beate , Girsch Werner , Windhager Reinhard , Fischer Michael B

The switch from a cartilage template to bone during endochondralossification of the growth plate requires dynamic and close interaction between the cartilage and the developing vascular structures. Vascular invasion of hypertrophic cartilage, with blood vessels coming from the bone collar, serves to bring in osteoblast- andendothelial precursor cells along with chondroclasts and their precursors into future ossification centres of the growth plate.Potent...

ba0001pp160 | Cancer and bone: basic, translational and clinical | ECTS2013

Glucose ceramide synthase inhibitors prevent osteoclast activation and limit myeloma-induced osteolytic lesions

Ersek Adel , Xu Ke , Karadimitris Anastasios , Horwood Nicole J

Glycosphingolipids (GSL) are essential structural components of mammalian cell membranes and lipid rafts that exert pleiotropic effects on cell survival, proliferation, and differentiation. Cancer associated GSL have been shown to promote tumor growth, angiogenesis, and metastasis; however their role in osteoclast (OC) activation and the development of osteolytic bone diseases such as multiple myeloma are not known. We investigated the hypothesis that GSL contribute to OC acti...

ba0003pp187 | Genetics | ECTS2014

A novel mutation in IFITM5, encoding BRIL, impairs osteoblast production of PEDF and causes atypical type VI osteogenesis imperfecta

Reich Adi , Farber Charles R , Barnes Aileen M , Becerra Patricia , Rauch Frank , Cabral Wayne A , Bae Alison , Glorieux Francis H , Clemens Thomas L , Marini Joan C

Osteogenesis imperfecta (OI) type V is caused by a unique dominant mutation (c.−14C>T) in IFITM5, which encodes BRIL, a transmembrane ifitm-like protein most strongly expressed in osteoblasts, while type VI OI is caused by recessive null mutations in SERPINF1, encoding pigment epithelium-derived factor (PEDF). We identified a 25-year-old woman with severe OI, whose dermal fibroblasts and cultured osteoblasts displayed minimal secretion of PEDF, but ...

ba0003pp267 | Osteoporosis: pathophysiology and epidemiology | ECTS2014

Fracture risk and the osteoporosis treatment care gap in patients with type 1 diabetes

Khan Tayyab , Spaic Tamara , Fraser Lisa-Ann

Individuals with type 1 diabetes have over a sixfold increased risk of sustaining a hip fracture compared to the general population. Despite this, bone fragility is not recognized as a classic diabetes-related complication and many diabetes guidelines make no mention of fracture prevention or bone health.We studied bone health in a population of patients with known type 1 diabetes being followed by endocrinologists at an academic centre. Patients filled ...